Open Challenge

Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge: Phase II Stage I 2026–2027

NIH Common Fund prize challenge for developing an initial endogenous RNA-targeting technology prototype and disease use case; Phase II Stage I submissions open December 1, 2026 and close February 1, 2027.

FindMyMoney.App
Published by FindMyMoney.App
Official source: National Institutes of Health (NIH) Common Fund
💰 Funding $120,000 per Stage I winner, up to 25 winners; $3,000,000 Stage I prize pool
📅 Deadline Feb 1, 2027
📍 Location United States
🏛️ Source National Institutes of Health (NIH) Common Fund

Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge: Phase II Stage I 2026–2027

Status: announced; submissions open December 1, 2026 and close February 1, 2027. NIH has launched the Phase II: Stage I interim milestone competition. The official NIH announcement says Phase I participation is not required. The submission window has not opened yet. The published closing date is February 1, 2027. This is an active, upcoming opportunity, so this listing is not marked as a historical reference.

What the challenge supports

The Targeting RNA in Disease with Novel Technologies Challenge is run by the National Institutes of Health Common Fund through its Venture Program. Its aim is to help develop and disseminate new technologies that treat disease by acting on endogenous RNA. The challenge focuses on two broad opportunities: disease caused by RNA dysfunction, and disease driven by proteins that are difficult to target directly with conventional small molecules but may be influenced upstream at the RNA level.

The competition is a prize challenge rather than a grant application. Phase II asks participants to move beyond an idea and develop an initial RNA-targeting technology prototype. A submission must pair the technology with a human-disease-relevant use case, define measurable evidence of progress and efficacy, and explain how the technology could become publicly accessible. The design should have potential to serve more than one disease or disease class, even though the proposal needs a concrete use case for demonstrating and testing it.

NIH identifies several possible areas of work, including approaches that change RNA interactions with RNA-binding proteins to affect splicing, stability, or translation; targeting long non-coding RNAs; assays that identify native RNA–protein interactions and evaluate therapeutic effects; screening libraries enriched for RNA-targeting small molecules; and methods that alter abnormal RNA structures. These examples are not an exhaustive list. The key scientific boundary is that competitive solutions target endogenous RNA to treat disease. Simply proposing an RNA molecule as a medicine does not meet that requirement by itself.

Phase II Stage I award

Stage I offers an interim milestone prize of $120,000 per winner, for up to 25 winners. The Stage I prize pool is up to $3,000,000. The NIH announcement describes the larger Phase II prize purse as up to $7,800,000, split between the current Stage I and a later Stage II. Stage II is a separate final-submission competition for Stage I interim winners; its current announcement lists prizes of up to $320,000 per winner for up to 15 winners. Those later-stage amounts are not part of the Stage I award and do not make a Stage II application open now.

The overall three-phase prize plan may total up to $13,100,000 if NIH launches the subsequent phase and funds are available. NIH states that later challenge phases and prizes are discretionary and contingent on appropriated funds. Thus, applicants should assess this opportunity on the basis of the announced Stage I terms. A prize is not guaranteed merely because a submission is complete, and NIH reserves the right not to award prizes if submissions are not judged worthy.

Prize payments are made electronically and may be subject to federal income taxes. Entities are encouraged, but not required, to obtain a Unique Entity ID through SAM.gov if they do not already have one, as it may expedite payment. The award is a prize for milestone progress rather than a reimbursement budget or a grant with standard indirect-cost support.

Who may participate

An individual, independent team, or entity may participate if it meets the NIH announcement’s rules. To receive a cash prize, an individual participant must be a U.S. citizen or permanent resident. A private entity must be incorporated in the United States and maintain its primary place of business there. Non-U.S. citizens and non-permanent residents can be members of a team that otherwise satisfies the eligibility conditions, but they cannot receive any portion of a monetary prize. Participants must be at least 18 years old when they submit.

A federal entity or a federal employee acting within the scope of employment may not participate as an eligible prize recipient. An employee of the Department of Health and Human Services, including its components, may not participate in a personal capacity. Employees of other federal agencies should consult their agency ethics official about whether applicable ethics rules limit participation or prize acceptance. Challenge judges, people involved in the challenge’s design, production, execution, or distribution, and their immediate family members are also excluded.

Federal grantees and recipients of cooperative agreements or other-transaction awards may participate, but they may use federal funds for challenge work only when that use is consistent with their award’s purpose and terms. Anyone intending to use those funds must register and participate as an entity on behalf of the awardee institution or organization. The NIH rules also bar federal contractors from using federal contract funds to develop their entries or support submission work. Applicants should coordinate with the responsible award or institutional official when federal funding is involved.

The rules grant NIH a nonexclusive license to publicly reproduce, post, share, and display submissions, while participants retain their other intellectual-property rights. Participants also agree to a nonexclusive license for noncommercial educational or research use. Since the title and executive summary may be shared publicly, do not place proprietary or confidential details in those sections. Participants should review the full NIH announcement and applicable institutional obligations before submitting.

What the Stage I submission must contain

The submission describes a technology that has made initial progress toward a prototype, not just a future concept. NIH requests a title and executive summary, then information addressing all three Stage I milestones. The executive summary should briefly explain the technology and how it could help develop RNA-targeting therapies across multiple diseases. Keep confidential and proprietary details out of the title and summary.

Milestone 1: Prototype design and progress. Explain the significant health need and the endogenous RNA target or target class. Describe how the platform works, why the design is innovative relative to established methods, what has already been constructed or tested, and what initial performance testing demonstrates. Give enough technical detail to show the technology’s capabilities and a credible route to further development. NIH also considers whether the design can extend across diseases or disease classes.

Milestone 2: Early validation plan. Identify a specific human-disease-relevant use case and explain why it is a suitable early test of the technology. Lay out the expected validation steps, the outputs to be measured, and the quantitative success metrics. The use case should make clear how the technology will engage or modulate its RNA target and how the proposed measurements will show whether it works in the chosen context.

Milestone 3: Early dissemination plan. Describe how the technology could be made publicly accessible. Explain the team’s ability to develop and disseminate it, the feasibility of the proposed access approach, and whether that approach could lead to an open-access product or a marketable product. NIH asks teams to consider appropriate engagement with end users, industry, regulatory groups, and patient communities, as relevant, and to identify proposed collaborators or partners where useful.

Stage I does not require the complete Public Access and Dissemination Plan (PADP) that is required for the later Stage II. It does require an early-stage description of the dissemination approach, and NIH advises participants to keep the final PADP expectations in view. Stage II is limited to Stage I interim milestone winners and will require a final performance-tested prototype, a documented disease use case providing early-stage validation, and a final PADP, including recruited external partners where needed.

How to apply

  1. Read the Phase II: Stage I announcement and rules. Confirm that the proposed solution targets endogenous RNA for a disease-related purpose. Review the eligibility provisions, participation terms, judging milestones, intellectual-property language, and the full submission format before preparing material.
  2. Register through the official TRDNT challenge site. NIH identifies trdntchallenge.com as the official registration and submission site. Registration asks whether the entrant is an independent team or an entity and collects names, affiliations, and contact information for all participants. Participants must acknowledge whether federal funding will be used and certify agreement to the published rules.
  3. Assign the required representative. Each team names a Team Captain, who registers and submits for the team and handles sponsor communications. The Team Captain must be a U.S. citizen or permanent resident to receive a team prize. An entity names a Point of Contact; a winning entity receives its prize directly. Entries using federal grant, cooperative agreement, or other-transaction funds must register as the awardee entity.
  4. Prepare a complete response to all three milestones. Include initial prototype development and performance progress, a specific validation use case with measurable outcomes, and an early dissemination plan. Address the scientific and technical rationale alongside the team’s relevant expertise, resources, validation approach, and access strategy.
  5. Format and submit the entry in the portal. NIH requires a single PDF on 8.5-by-11-inch pages, with margins of at least one inch, English text, Arial font no smaller than 11 point, and line spacing of at least 1.0. Follow any page-length limit supplied in the portal. Do not use the HHS or NIH logo or official seal, and do not imply federal endorsement. The complete submission must be entered in the portal by 11:59 p.m. Eastern Time on the closing date.

The official announcement says the Stage I submission period opens December 1, 2026 and closes February 1, 2027. Registration and submissions should be completed through the challenge portal during that window. Check the portal for operational instructions and any details NIH adds before submissions open. The funding-opportunities table on the NIH Common Fund site has displayed an inconsistent close year; use the specific Phase II: Stage I NIH challenge announcement, which states February 1, 2027, as the authoritative deadline.

How NIH evaluates entries

Complete entries are reviewed by technical experts with relevant subject-matter expertise. Federal employee judges select interim milestone winners, subject to the Award Approving Official’s final decision. NIH says all milestones must be met for a submission to be considered for an interim prize.

Prototype design is worth 40 points. Reviewers consider whether the platform targets endogenous RNA, whether it is innovative compared with existing methods, whether the development details support confidence that it can be built, whether progress toward initial performance testing is credible, and whether the technology could extend across multiple diseases. Early validation planning is worth 30 points and is assessed for the viability of the use case, the quality and measurability of the proposed validation steps, and the likelihood of success in the selected context. Early dissemination planning is worth 30 points and covers the team’s capacity, the feasibility of the access plan, and engagement with relevant end-user or stakeholder communities.

A persuasive submission will connect each claim to a practical demonstration. It should identify what has already been designed or constructed, distinguish preliminary results from future work, explain what the next experiments measure, and show how the chosen use case tests a meaningful disease-relevant function. The dissemination plan should be integrated into the technical path so that the proposed route from prototype to accessible technology is plausible.

Timeline and what happens after Stage I

NIH’s published schedule lists the Phase II Stage I launch in August 2026, submissions from December 1, 2026 through February 1, 2027, judging during February and March 2027, and winner announcements in March 2027. These dates describe the announced Stage I schedule; applicants should follow the official announcement and registration portal for any formal updates.

NIH anticipates Stage II final submissions later, with a separate announcement and requirements. Only Stage I interim winners may advance to that phase. NIH also anticipates a possible Phase III focused on final iteration and technology dissemination, open only to Phase II Stage II winners. The NIH announcement says new announcements will provide the requirements, registration details, and judging criteria for later phases. Those future phases are contingent on NIH discretion and appropriated funds, so their planned schedule and prizes are not a current application invitation.

The controlling source for this listing is the NIH Phase II: Stage I challenge announcement. NIH Common Fund’s TRDNT program page provides background, and the official challenge site handles registration and submission. Read the full announcement for terms, updates, and any portal-specific instructions before applying.

Next step
Apply Now